BHB & CAR-T for Lymphomas

Inclusion Criteria

• •Age of 18 years or older
• •History of pathologically-confirmed large B-cell lymphoma (LBCL)
• •Planned treatment with a commercially available anti-CD19 CAR-T product (Yescarta or Kymriah)
• •Eligible for and with adequate organ function (investigator discretion) and performance status (ECOG PS 2 or less) for standard of care, anti-CD19 CAR-T
• •Not enrolled on a clinical trial of bridging therapy prior to CAR-T
• •Patients must have a PET/CT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesions or ≥ 1cm for extra- nodal lesions in largest dimension by low-dose computerized tomography \[CT\] scan with FDG-uptake ≥ liver) documented prior to leukapheresis for CAR-T manufacturing
• •Resolution of toxicities from prior therapy to a grade that does not contraindicate trial participation in the opinion of the investigator
• •Can provide informed consent
• •Willing to comply with all study procedures and available for the duration of the study